OpGen’s Subsidiary Ares Genetics Releases New Features to its AREScloud Offering
- Single nucleotide polymorphism (SNP) analysis module and interpretation of plasmids now available
- Added reporting customized for the needs of hospital epidemiologists
- Signed first large commercial contract with
U.S.healthcare network using the new features
Genomic surveillance uses prospective whole genome sequencing (WGS) of all relevant pathogen isolates in a healthcare setting to identify hospital associated infections (HAIs) in real-time and enable preventive measures to limit outbreaks. Working with its customers globally, the Ares team has developed the new AREScloud features to provide relevant reporting for hospital epidemiologists and infection preventionists.
These specific new AREScloud features include:
- a new single nucleotide polymorphism (SNP) analysis module designed to support continuous analysis of new isolates as part of an ongoing genomic surveillance program,
- a new module for interpretation of genetic elements such as plasmids responsible for horizontal gene transmission,
- results reporting specifically for the needs of hospital epidemiologists and infection prevention staff, and
- compliance with HIPAA and SOCS2 standards, with auditing expected to be completed in Q3.
The new AREScloud features are now deployed as part of the standard analysis package, and in use with our customers globally. This includes a genomic surveillance contract with a large
Theo deVos, Ares Genetics Managing Director commented: “We are focused on bringing improved patient care with the published benefits of genomic surveillance to healthcare providers in the
About OpGen, Inc.
For more information, please visit www.opgen.com.
This press release includes statements regarding the release of new features in the AREScloud offering. These statements and other statements regarding OpGen’s future plans and goals constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control, and which may cause results to differ materially from expectations. Factors that could cause our results to differ materially from those described include, but are not limited to, the success of our commercialization efforts, our ability to successfully, timely and cost-effectively develop, seek and obtain regulatory clearance for and commercialize our product and services offerings, the rate of adoption of our products and services by hospitals and other healthcare providers, the fact that we may not effectively use proceeds from recent financings, our ability to satisfy debt obligations under our loan with the
President and CEO
OpGen Investor & Press Contact:
Source: OpGen, Inc.